Corcept Therapeutics Incorporated CORT Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

May 02, 2024 (filed on May 06, 2024)

Insider Name:

Lyon Joseph Douglas

Ownership Type:

Direct Ownership

Securities:

Stock option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-10,830

Price:

--
May 02, 2024 (filed on May 06, 2024)

Insider Name:

Lyon Joseph Douglas

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,830

Price:

$26.00
May 02, 2024 (filed on May 06, 2024)

Insider Name:

Lyon Joseph Douglas

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

10,830

Price:

$11.35
May 01, 2024 (filed on May 03, 2024)

Insider Name:

Swisher Daniel N JR

Ownership Type:

Direct Ownership

Securities:

Stock option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,200

Price:

--
May 01, 2024 (filed on May 03, 2024)

Insider Name:

Swisher Daniel N JR

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,200

Price:

$23.09
May 01, 2024 (filed on May 03, 2024)

Insider Name:

Swisher Daniel N JR

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

2,200

Price:

$5.86
Apr 10, 2024 (filed on Apr 12, 2024)

Insider Name:

Mahoney David L

Ownership Type:

Direct Ownership

Securities:

Stock option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-30,000

Price:

--
Apr 10, 2024 (filed on Apr 12, 2024)

Insider Name:

Mahoney David L

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

27,806

Price:

--
Apr 10, 2024 (filed on Apr 12, 2024)

Insider Name:

Mahoney David L

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

-27,806

Price:

--
Apr 10, 2024 (filed on Apr 12, 2024)

Insider Name:

Mahoney David L

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,194

Price:

$23.80

Filings by filing date

May 02, 2024 (filed on May 06, 2024)

Insider Name:

Lyon Joseph Douglas

Ownership Type:

Direct Ownership

Securities:

Stock option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-10,830

Price:

--
May 02, 2024 (filed on May 06, 2024)

Insider Name:

Lyon Joseph Douglas

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-10,830

Price:

$26.00
May 02, 2024 (filed on May 06, 2024)

Insider Name:

Lyon Joseph Douglas

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

10,830

Price:

$11.35
May 01, 2024 (filed on May 03, 2024)

Insider Name:

Swisher Daniel N JR

Ownership Type:

Direct Ownership

Securities:

Stock option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-2,200

Price:

--
May 01, 2024 (filed on May 03, 2024)

Insider Name:

Swisher Daniel N JR

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,200

Price:

$23.09
May 01, 2024 (filed on May 03, 2024)

Insider Name:

Swisher Daniel N JR

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

2,200

Price:

$5.86
Apr 10, 2024 (filed on Apr 12, 2024)

Insider Name:

Mahoney David L

Ownership Type:

Direct Ownership

Securities:

Stock option (right to buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-30,000

Price:

--
Apr 10, 2024 (filed on Apr 12, 2024)

Insider Name:

Mahoney David L

Ownership Type:

Indirect Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

27,806

Price:

--
Apr 10, 2024 (filed on Apr 12, 2024)

Insider Name:

Mahoney David L

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

-27,806

Price:

--
Apr 10, 2024 (filed on Apr 12, 2024)

Insider Name:

Mahoney David L

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-2,194

Price:

$23.80

News

Biz Brief

Sector: Healthcare	Industry: Pharmaceuticals

See Regulatory Filings on SEC

Company Contact

Address:	149 Commonwealth Dr MENLO PARK CA 94025
Tel:	N/A
Website:	https://www.corcept.com
IR:	See website

Key People

Joseph K. Belanoff President, Chief Executive Officer, Co-Founder, Director	Atabak Mokari Chief Financial Officer, Treasurer	Sean Maduck President - Corcept Endocrinology
Monica Tellado President, Emerging Markets	Roberto Vieira President - Oncology	Joseph Douglas Lyon Chief Accounting Officer
Hazel Hunt Chief Scientific Officer	William Guyer Chief Development Officer	Gary Charles Robb Chief Business Officer, Secretary

Business Overview

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Financial Overview

For the three months ended 31 March 2024, Corcept Therapeutics Incorporated revenues increased 39% to $146.8M. Net income increased 75% to $27.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Interest Income - Non Bank increase of 53% to $5.5M (income). Basic Earnings per Share excluding Extraordinary Items increased from $0.15 to $0.27.

Employees:	352 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$2,085M as of Mar 31, 2024
Annual revenue (TTM):	$523.53M as of Mar 31, 2024
EBITDA (TTM):	$122.92M as of Mar 31, 2024
Net annual income (TTM):	$118.02M as of Mar 31, 2024
Free cash flow (TTM):	$124.70M as of Mar 31, 2024
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	104,112,088 as of Apr 24, 2024
Index Membership:	S&P 600 Small Cap
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization